Patel Naimish's Form 4 filing
CRISPR Therapeutics AG (CRSP) · filed Jan 27, 2026
- Accession no.
- 0001193125-26-024955
- Filed
- Jan 27, 2026
- Trade date
- Apr 3, 2025
- Filing delay
- 299 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $49.7K. It was filed 299 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patel NaimishCIK 0002021679 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2025 | Common Shares | PPurchaseAcquired | +1,508 | $32.96 | +$49,703.68 | 1,508 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.